The present invention relates to compounds of formula I
wherein A and R
1
to R
4
are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same
申请人:Man Hon-Wah
公开号:US20110196150A1
公开(公告)日:2011-08-11
Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
[EN] HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS<br/>[FR] HETEROARYL-UREES ET LEUR UTILISATION EN TANT QU'ACTIVATEURS DE GLUCOKINASE
申请人:NOVO NORDISK AS
公开号:WO2005066145A1
公开(公告)日:2005-07-21
This invention relates to compounds that are of formula (I) wherein A is heteroaryl and R1 and R2 are both cyclic residues, that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial .
ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
申请人:Celgene Corporation
公开号:US20180037567A1
公开(公告)日:2018-02-08
Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
Heteroaryl-Ureas and Their Use as Glucokinase Activators
申请人:Murray Anthony
公开号:US20090216013A1
公开(公告)日:2009-08-27
This invention relates to compounds of formula (I)
which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.